Clinical Trial Update: Proof-of-concept Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of SION-719 When Added to Trikafta [Phase 2]

View source ↗

Summary

A Phase 2 proof-of-concept trial is evaluating the safety, tolerability, pharmacodynamics, and pharmacokinetics of SION-719 when added to Trikafta in cystic fib…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• SION-719
• TRIKAFTA (ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR)

Snippet

Sponsor: Sionna Therapeutics Inc. | Conditions: Cystic Fibrosis (CF) | Phase 2 | Status: RECRUITING